Market Overview:
The global fibroblast growth factor receptor 2 inhibitor market is expected to grow at a CAGR of XX% during the forecast period from 2018 to 2030. The market is segmented on the basis of type, application and region. On the basis of type, the market is segmented into ASP-5878, AZD-4547, BAY-1163877, CPL-043, Debio-1347, EDP-317 and others. On the basis of application, the market is segmented into clinic and hospital. The North America region dominates this market followed by Europe and Asia Pacific regions respectively.
Product Definition:
A fibroblast growth factor receptor 2 inhibitor is a type of drug that blocks the action of the fibroblast growth factor receptor 2 (FGFR2) protein. FGFR2 is involved in the growth and spread of cancer cells, so blocking its action can help to stop or slow down tumor growth.
ASP-5878:
ASP-5878 is a selective inhibitor of FGF22. It has shown potent growth factor receptor 2 (FGFR2) inhibitory activity in vitro and in vivo, with an IC 50 value of 0.4 uM. ASP-5878 was identified as a novel molecule that can be used for the treatment of R/R articular arthritis by Teva Pharmaceuticals Ltd., Israel on the basis of its pharmacological profile and preclinical safety & efficacy data in 2016.
AZD-4547:
Fibroblast growth factor receptor 2 (FGFR2) is a protein that in humans is encoded by the FGFR2 gene. The product of this gene plays an important role in the proliferation and differentiation of fibroblasts. AZD-4547 is a drug, which targets FGFR2 for the treatment of multiple myeloma and renal cell carcinoma.
Application Insights:
The others segment held the largest share of the global fibroblast growth factor receptor 2 inhibitor market in 2017. This is due to a high product demand from other applications, such as cosmetic and plastic surgery. In addition, this application segment is expected to grow at a lucrative rate over the forecast period owing to increasing product approvals for various indications across all regions.
Hospital was the second largest application of these drugs in 2017 and it is projected to grow with CAGR around 11% from 2018 to 2030. Increasing hospital admissions for conditions that respond well to treatment with FGF21 are driving this growth. Furthermore, growing awareness about diseases associated with aging skin coupled with rising approval of products for anti-aging treatments will boost industry expansion over the forecast period (2018 - 2030).
Increasing adoption of aesthetic procedures such as plastic surgeries.
Regional Analysis:
North America dominated the global market in 2017. This can be attributed to the presence of key players, high R&D investment by companies and increased focus on drug development. The region is expected to maintain its position during the forecast period due to increasing investments in Fibroblast Growth Factor Receptor 2 (FGF2R) inhibitor-based research programs by major pharmaceutical companies such as Pfizer Inc., Merck & Co., Inc., and FUJIFILM Diosynth Biotechnologies U.S.
Asia Pacific is expected to grow at a lucrative rate over the forecast period owing to rising healthcare expenditure, growing patient awareness levels coupled with an increase in demand for advanced therapeutics for treatment of various diseases especially cancer and diabetes is anticipated drive growth over this region.
Growth Factors:
- Increasing prevalence of cancer: The increasing prevalence of cancer is one of the major growth drivers for the Fibroblast Growth Factor Receptor 2 Inhibitor market. According to the American Cancer Society, in 2016, an estimated 1,685,210 new cases of cancer will be diagnosed in the U.S., and 595,690 people will die from the disease. This number is expected to rise in future due to growing population and aging population.
- Rising demand for targeted therapies: The rising demand for targeted therapies is another major growth driver for the Fibroblast Growth Factor Receptor 2 Inhibitor market. Targeted therapies are drugs that are designed to attack specific cells or proteins in the body that contribute to tumor growth and progression. They offer a more personalized approach to treatment as they can be tailored according to each individual’s genetic makeup or biomarkers present on their tumor cells.
Scope Of The Report
Report Attributes
Report Details
Report Title
Fibroblast Growth Factor Receptor 2 Inhibitor Market Research Report
By Type
ASP-5878, AZD-4547, BAY-1163877, CPL-043, Debio-1347, EDP-317, Others
By Application
Clinic, Hospital, Others
By Companies
Advenchen Laboratories, Amgen, ArQule, Santa Cruz Biotechnology, AstraZeneca, AVEO Pharmaceuticals, Batu Biologics, Boehringer Ingelheim, Bristol-Myers Squibb Company, Celon Pharma, Debiopharm International, Eddingpharm, Eisai, Eli Lilly and Company, Hutchison MediPharma, Novartis, Principia Biopharma, Vichem Chemie Research
Regions Covered
North America, Europe, APAC, Latin America, MEA
Base Year
2021
Historical Year
2019 to 2020 (Data from 2010 can be provided as per availability)
Forecast Year
2030
Number of Pages
199
Number of Tables & Figures
140
Customization Available
Yes, the report can be customized as per your need.
Global Fibroblast Growth Factor Receptor 2 Inhibitor Market Report Segments:
The global Fibroblast Growth Factor Receptor 2 Inhibitor market is segmented on the basis of:
Types
ASP-5878, AZD-4547, BAY-1163877, CPL-043, Debio-1347, EDP-317, Others
The product segment provides information about the market share of each product and the respective CAGR during the forecast period. It lays out information about the product pricing parameters, trends, and profits that provides in-depth insights of the market. Furthermore, it discusses latest product developments & innovation in the market.
Applications
Clinic, Hospital, Others
The application segment fragments various applications of the product and provides information on the market share and growth rate of each application segment. It discusses the potential future applications of the products and driving and restraining factors of each application segment.
Some of the companies that are profiled in this report are:
- Advenchen Laboratories
- Amgen
- ArQule
- Santa Cruz Biotechnology
- AstraZeneca
- AVEO Pharmaceuticals
- Batu Biologics
- Boehringer Ingelheim
- Bristol-Myers Squibb Company
- Celon Pharma
- Debiopharm International
- Eddingpharm
- Eisai
- Eli Lilly and Company
- Hutchison MediPharma
- Novartis
- Principia Biopharma
- Vichem Chemie Research
Highlights of The Fibroblast Growth Factor Receptor 2 Inhibitor Market Report:
- The market structure and projections for the coming years.
- Drivers, restraints, opportunities, and current trends of market.
- Historical data and forecast.
- Estimations for the forecast period 2030.
- Developments and trends in the market.
- By Type:
- ASP-5878
- AZD-4547
- BAY-1163877
- CPL-043
- Debio-1347
- EDP-317
- Others
- By Application:
- Clinic
- Hospital
- Others
- Market scenario by region, sub-region, and country.
- Market share of the market players, company profiles, product specifications, SWOT analysis, and competitive landscape.
- Analysis regarding upstream raw materials, downstream demand, and current market dynamics.
- Government Policies, Macro & Micro economic factors are also included in the report.
We have studied the Fibroblast Growth Factor Receptor 2 Inhibitor Market in 360 degrees via. both primary & secondary research methodologies. This helped us in building an understanding of the current market dynamics, supply-demand gap, pricing trends, product preferences, consumer patterns & so on. The findings were further validated through primary research with industry experts & opinion leaders across countries. The data is further compiled & validated through various market estimation & data validation methodologies. Further, we also have our in-house data forecasting model to predict market growth up to 2030.
Regional Analysis
- North America
- Europe
- Asia Pacific
- Middle East & Africa
- Latin America
Note: A country of choice can be added in the report at no extra cost. If more than one country needs to be added, the research quote will vary accordingly.
The geographical analysis part of the report provides information about the product sales in terms of volume and revenue in regions. It lays out potential opportunities for the new entrants, emerging players, and major players in the region. The regional analysis is done after considering the socio-economic factors and government regulations of the countries in the regions.
How you may use our products:
- Correctly Positioning New Products
- Market Entry Strategies
- Business Expansion Strategies
- Consumer Insights
- Understanding Competition Scenario
- Product & Brand Management
- Channel & Customer Management
- Identifying Appropriate Advertising Appeals
8 Reasons to Buy This Report
- Includes a Chapter on the Impact of COVID-19 Pandemic On the Market
- Report Prepared After Conducting Interviews with Industry Experts & Top Designates of the Companies in the Market
- Implemented Robust Methodology to Prepare the Report
- Includes Graphs, Statistics, Flowcharts, and Infographics to Save Time
- Industry Growth Insights Provides 24/5 Assistance Regarding the Doubts in the Report
- Provides Information About the Top-winning Strategies Implemented by Industry Players.
- In-depth Insights On the Market Drivers, Restraints, Opportunities, and Threats
- Customization of the Report Available
Frequently Asked Questions?
Fibroblast Growth Factor Receptor 2 Inhibitor is a medication that blocks the action of fibroblast growth factor receptors. This can reduce the growth of tumors or other abnormal cells.
Some of the major players in the fibroblast growth factor receptor 2 inhibitor market are Advenchen Laboratories, Amgen, ArQule, Santa Cruz Biotechnology, AstraZeneca, AVEO Pharmaceuticals, Batu Biologics, Boehringer Ingelheim, Bristol-Myers Squibb Company, Celon Pharma, Debiopharm International, Eddingpharm, Eisai, Eli Lilly and Company, Hutchison MediPharma, Novartis, Principia Biopharma, Vichem Chemie Research.
Chapter 1 Executive Summary
Chapter 2 Assumptions and Acronyms Used
Chapter 3 Research Methodology
Chapter 4 Fibroblast Growth Factor Receptor 2 Inhibitor Market Overview
4.1 Introduction
4.1.1 Market Taxonomy
4.1.2 Market Definition
4.1.3 Macro-Economic Factors Impacting the Market Growth
4.2 Fibroblast Growth Factor Receptor 2 Inhibitor Market Dynamics
4.2.1 Market Drivers
4.2.2 Market Restraints
4.2.3 Market Opportunity
4.3 Fibroblast Growth Factor Receptor 2 Inhibitor Market - Supply Chain Analysis
4.3.1 List of Key Suppliers
4.3.2 List of Key Distributors
4.3.3 List of Key Consumers
4.4 Key Forces Shaping the Fibroblast Growth Factor Receptor 2 Inhibitor Market
4.4.1 Bargaining Power of Suppliers
4.4.2 Bargaining Power of Buyers
4.4.3 Threat of Substitution
4.4.4 Threat of New Entrants
4.4.5 Competitive Rivalry
4.5 Global Fibroblast Growth Factor Receptor 2 Inhibitor Market Size & Forecast, 2018-2028
4.5.1 Fibroblast Growth Factor Receptor 2 Inhibitor Market Size and Y-o-Y Growth
4.5.2 Fibroblast Growth Factor Receptor 2 Inhibitor Market Absolute $ Opportunity
Chapter 5 Global Fibroblast Growth Factor Receptor 2 Inhibitor Market Analysis and Forecast by Type
5.1 Introduction
5.1.1 Key Market Trends & Growth Opportunities by Type
5.1.2 Basis Point Share (BPS) Analysis by Type
5.1.3 Absolute $ Opportunity Assessment by Type
5.2 Fibroblast Growth Factor Receptor 2 Inhibitor Market Size Forecast by Type
5.2.1 ASP-5878
5.2.2 AZD-4547
5.2.3 BAY-1163877
5.2.4 CPL-043
5.2.5 Debio-1347
5.2.6 EDP-317
5.2.7 Others
5.3 Market Attractiveness Analysis by Type
Chapter 6 Global Fibroblast Growth Factor Receptor 2 Inhibitor Market Analysis and Forecast by Applications
6.1 Introduction
6.1.1 Key Market Trends & Growth Opportunities by Applications
6.1.2 Basis Point Share (BPS) Analysis by Applications
6.1.3 Absolute $ Opportunity Assessment by Applications
6.2 Fibroblast Growth Factor Receptor 2 Inhibitor Market Size Forecast by Applications
6.2.1 Clinic
6.2.2 Hospital
6.2.3 Others
6.3 Market Attractiveness Analysis by Applications
Chapter 7 Global Fibroblast Growth Factor Receptor 2 Inhibitor Market Analysis and Forecast by Region
7.1 Introduction
7.1.1 Key Market Trends & Growth Opportunities by Region
7.1.2 Basis Point Share (BPS) Analysis by Region
7.1.3 Absolute $ Opportunity Assessment by Region
7.2 Fibroblast Growth Factor Receptor 2 Inhibitor Market Size Forecast by Region
7.2.1 North America
7.2.2 Europe
7.2.3 Asia Pacific
7.2.4 Latin America
7.2.5 Middle East & Africa (MEA)
7.3 Market Attractiveness Analysis by Region
Chapter 8 Coronavirus Disease (COVID-19) Impact
8.1 Introduction
8.2 Current & Future Impact Analysis
8.3 Economic Impact Analysis
8.4 Government Policies
8.5 Investment Scenario
Chapter 9 North America Fibroblast Growth Factor Receptor 2 Inhibitor Analysis and Forecast
9.1 Introduction
9.2 North America Fibroblast Growth Factor Receptor 2 Inhibitor Market Size Forecast by Country
9.2.1 U.S.
9.2.2 Canada
9.3 Basis Point Share (BPS) Analysis by Country
9.4 Absolute $ Opportunity Assessment by Country
9.5 Market Attractiveness Analysis by Country
9.6 North America Fibroblast Growth Factor Receptor 2 Inhibitor Market Size Forecast by Type
9.6.1 ASP-5878
9.6.2 AZD-4547
9.6.3 BAY-1163877
9.6.4 CPL-043
9.6.5 Debio-1347
9.6.6 EDP-317
9.6.7 Others
9.7 Basis Point Share (BPS) Analysis by Type
9.8 Absolute $ Opportunity Assessment by Type
9.9 Market Attractiveness Analysis by Type
9.10 North America Fibroblast Growth Factor Receptor 2 Inhibitor Market Size Forecast by Applications
9.10.1 Clinic
9.10.2 Hospital
9.10.3 Others
9.11 Basis Point Share (BPS) Analysis by Applications
9.12 Absolute $ Opportunity Assessment by Applications
9.13 Market Attractiveness Analysis by Applications
Chapter 10 Europe Fibroblast Growth Factor Receptor 2 Inhibitor Analysis and Forecast
10.1 Introduction
10.2 Europe Fibroblast Growth Factor Receptor 2 Inhibitor Market Size Forecast by Country
10.2.1 Germany
10.2.2 France
10.2.3 Italy
10.2.4 U.K.
10.2.5 Spain
10.2.6 Russia
10.2.7 Rest of Europe
10.3 Basis Point Share (BPS) Analysis by Country
10.4 Absolute $ Opportunity Assessment by Country
10.5 Market Attractiveness Analysis by Country
10.6 Europe Fibroblast Growth Factor Receptor 2 Inhibitor Market Size Forecast by Type
10.6.1 ASP-5878
10.6.2 AZD-4547
10.6.3 BAY-1163877
10.6.4 CPL-043
10.6.5 Debio-1347
10.6.6 EDP-317
10.6.7 Others
10.7 Basis Point Share (BPS) Analysis by Type
10.8 Absolute $ Opportunity Assessment by Type
10.9 Market Attractiveness Analysis by Type
10.10 Europe Fibroblast Growth Factor Receptor 2 Inhibitor Market Size Forecast by Applications
10.10.1 Clinic
10.10.2 Hospital
10.10.3 Others
10.11 Basis Point Share (BPS) Analysis by Applications
10.12 Absolute $ Opportunity Assessment by Applications
10.13 Market Attractiveness Analysis by Applications
Chapter 11 Asia Pacific Fibroblast Growth Factor Receptor 2 Inhibitor Analysis and Forecast
11.1 Introduction
11.2 Asia Pacific Fibroblast Growth Factor Receptor 2 Inhibitor Market Size Forecast by Country
11.2.1 China
11.2.2 Japan
11.2.3 South Korea
11.2.4 India
11.2.5 Australia
11.2.6 South East Asia (SEA)
11.2.7 Rest of Asia Pacific (APAC)
11.3 Basis Point Share (BPS) Analysis by Country
11.4 Absolute $ Opportunity Assessment by Country
11.5 Market Attractiveness Analysis by Country
11.6 Asia Pacific Fibroblast Growth Factor Receptor 2 Inhibitor Market Size Forecast by Type
11.6.1 ASP-5878
11.6.2 AZD-4547
11.6.3 BAY-1163877
11.6.4 CPL-043
11.6.5 Debio-1347
11.6.6 EDP-317
11.6.7 Others
11.7 Basis Point Share (BPS) Analysis by Type
11.8 Absolute $ Opportunity Assessment by Type
11.9 Market Attractiveness Analysis by Type
11.10 Asia Pacific Fibroblast Growth Factor Receptor 2 Inhibitor Market Size Forecast by Applications
11.10.1 Clinic
11.10.2 Hospital
11.10.3 Others
11.11 Basis Point Share (BPS) Analysis by Applications
11.12 Absolute $ Opportunity Assessment by Applications
11.13 Market Attractiveness Analysis by Applications
Chapter 12 Latin America Fibroblast Growth Factor Receptor 2 Inhibitor Analysis and Forecast
12.1 Introduction
12.2 Latin America Fibroblast Growth Factor Receptor 2 Inhibitor Market Size Forecast by Country
12.2.1 Brazil
12.2.2 Mexico
12.2.3 Rest of Latin America (LATAM)
12.3 Basis Point Share (BPS) Analysis by Country
12.4 Absolute $ Opportunity Assessment by Country
12.5 Market Attractiveness Analysis by Country
12.6 Latin America Fibroblast Growth Factor Receptor 2 Inhibitor Market Size Forecast by Type
12.6.1 ASP-5878
12.6.2 AZD-4547
12.6.3 BAY-1163877
12.6.4 CPL-043
12.6.5 Debio-1347
12.6.6 EDP-317
12.6.7 Others
12.7 Basis Point Share (BPS) Analysis by Type
12.8 Absolute $ Opportunity Assessment by Type
12.9 Market Attractiveness Analysis by Type
12.10 Latin America Fibroblast Growth Factor Receptor 2 Inhibitor Market Size Forecast by Applications
12.10.1 Clinic
12.10.2 Hospital
12.10.3 Others
12.11 Basis Point Share (BPS) Analysis by Applications
12.12 Absolute $ Opportunity Assessment by Applications
12.13 Market Attractiveness Analysis by Applications
Chapter 13 Middle East & Africa (MEA) Fibroblast Growth Factor Receptor 2 Inhibitor Analysis and Forecast
13.1 Introduction
13.2 Middle East & Africa (MEA) Fibroblast Growth Factor Receptor 2 Inhibitor Market Size Forecast by Country
13.2.1 Saudi Arabia
13.2.2 South Africa
13.2.3 UAE
13.2.4 Rest of Middle East & Africa (MEA)
13.3 Basis Point Share (BPS) Analysis by Country
13.4 Absolute $ Opportunity Assessment by Country
13.5 Market Attractiveness Analysis by Country
13.6 Middle East & Africa (MEA) Fibroblast Growth Factor Receptor 2 Inhibitor Market Size Forecast by Type
13.6.1 ASP-5878
13.6.2 AZD-4547
13.6.3 BAY-1163877
13.6.4 CPL-043
13.6.5 Debio-1347
13.6.6 EDP-317
13.6.7 Others
13.7 Basis Point Share (BPS) Analysis by Type
13.8 Absolute $ Opportunity Assessment by Type
13.9 Market Attractiveness Analysis by Type
13.10 Middle East & Africa (MEA) Fibroblast Growth Factor Receptor 2 Inhibitor Market Size Forecast by Applications
13.10.1 Clinic
13.10.2 Hospital
13.10.3 Others
13.11 Basis Point Share (BPS) Analysis by Applications
13.12 Absolute $ Opportunity Assessment by Applications
13.13 Market Attractiveness Analysis by Applications
Chapter 14 Competition Landscape
14.1 Fibroblast Growth Factor Receptor 2 Inhibitor Market: Competitive Dashboard
14.2 Global Fibroblast Growth Factor Receptor 2 Inhibitor Market: Market Share Analysis, 2019
14.3 Company Profiles (Details – Overview, Financials, Developments, Strategy)
14.3.1 Advenchen Laboratories
14.3.2 Amgen
14.3.3 ArQule
14.3.4 Santa Cruz Biotechnology
14.3.5 AstraZeneca
14.3.6 AVEO Pharmaceuticals
14.3.7 Batu Biologics
14.3.8 Boehringer Ingelheim
14.3.9 Bristol-Myers Squibb Company
14.3.10 Celon Pharma
14.3.11 Debiopharm International
14.3.12 Eddingpharm
14.3.13 Eisai
14.3.14 Eli Lilly and Company
14.3.15 Hutchison MediPharma
14.3.16 Novartis
14.3.17 Principia Biopharma
14.3.18 Vichem Chemie Research
